East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg. Aurobindo Pharma’s Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), TRUVADA® Tablets manufactured by Gilead Science Inc.,

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are indicated in:

• Combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg.